In a phase 2 clinical trial , mapatumumab was well tolerated .
In a phase 2 clinical trial , mapatumumab could be administered safely in patients with advanced non-small - cell lung cancer ( NSCLC ) and advanced colorectal cancer .
In a phase 2 clinical trial , mapatumumab was well tolerated and could be administered safely in patients with advanced non-small - cell lung cancer ( NSCLC ) and advanced colorectal cancer .